Novo Nordisk: diabetes drug better than Merck's Januvia

(CercleFinance.com) - Denmark's Novo Nordisk, the world's biggest insulin producer, said that its oral semaglutide drug has showed superior reductions in blood sugar and weight compared to Merck's Januvia.


Oral semaglutide demonstrated superior blood sugar levels and body weight reductions compared to Januvia at 26 weeks for patients with type-2 diabetes, according to phase 3a results presented in the Journal of the American Medical Association, Novo said.

However, non-inferiority for oral semaglutide 3 mg for blood sugar reductions at 26 weeks was not confirmed, the drugmaker said.

Copyright (c) 2019 CercleFinance.com. All rights reserved.